☆ 4.4 Review

Adagrasib: a novel inhibitor for KRAS(G12C)-mutated non-small-cell lung cancer

FUTURE ONCOLOGY (2023)

Related references

Note: Only part of the references are listed.
Article Biochemistry & Molecular Biology

Inside the cracked kernel: establishing the molecular basis of AMG510 and MRTX849 in destabilising KRASG12C mutant switch I and II in cancer treatment

Abdul Rashid Issahaku et al.

Summary: In this study, computational tools were used to investigate the atomistic interactions and conformational effects of AMG510 and MRTX849 on mutant KRAS(G12C). The results showed that both drugs had strong binding affinities to mutant KRAS(G12C) and induced conformational changes in switch I and switch II, potentially disrupting the binding of effector proteins. These findings provide valuable insights into the success of AMG510 and MRTX849 and can guide the design of more selective and potent KRAS inhibitors.

JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2023)

Add to Collection
Article Oncology

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1)

Sai-Hong Ignatius Ou et al.

Summary: This study reported the results of a clinical trial using adagrasib to treat non-small-cell lung cancer, colorectal cancer, and other solid tumors with the KRAS(G12C) mutation. The recommended phase II dose was identified as 600 mg twice a day, and it demonstrated good tolerability and antitumor activity.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection
Review Oncology

The path to the clinic: a comprehensive review on direct KRASG12C inhibitors

Albert K. Kwan et al.

Summary: This article reviews the development of KRAS inhibitors, including the discovery and structure of the RAS family of oncoproteins, the clinical relevance of KRAS in human cancer, particularly the KRAS(G12C) mutation, and the ongoing clinical trials of direct KRAS(G12C) inhibitors.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)

Add to Collection
Review Oncology

Hallmarks of Cancer: New Dimensions

Douglas Hanahan

Summary: The concept of the hallmarks of cancer is a tool for simplifying the complexity of cancer phenotypes and genotypes into basic principles. This article proposes phenotypic plasticity and disrupted differentiation as distinct hallmark capabilities, and discusses nonmutational epigenetic reprogramming and polymorphic microbiomes as enabling characteristics. Additionally, the importance of senescent cells in the tumor microenvironment is highlighted. The integrative concept of the hallmarks of cancer helps in understanding the mechanisms of cancer development and applying that knowledge to cancer medicine.

CANCER DISCOVERY (2022)

Add to Collection
Article Oncology

Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer

Joshua K. Sabari et al.

Summary: Patients with KRAS-mutant NSCLC have a high propensity to develop brain metastases. Adagrasib has shown penetration into the cerebrospinal fluid and demonstrated antitumor activity in multiple preclinical models, supporting its potential clinical activity in the brain for patients with KRASG12C-mutant NSCLC and untreated brain metastases.

CLINICAL CANCER RESEARCH (2022)

Add to Collection
Article Oncology

Single agent VS-6766 or VS-6766 plus defactinib in KRAS-mutant non-small-cell lung cancer: the RAMP-202 phase II trial

Enrica Capelletto et al.

Summary: KRAS mutations occur in approximately 30% of lung adenocarcinomas, and current treatment options are limited to chemotherapy and immunotherapy. However, clinical trials exploring targeted agents are expected to change the treatment landscape of this disease.

FUTURE ONCOLOGY (2022)

Add to Collection
Article Oncology

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status

Biagio Ricciuti et al.

Summary: STK11 and KEAP1 mutations have a negative impact on the efficacy of immunotherapy in lung adenocarcinoma, but this effect is only observed in KRAS-positive tumors. Tumors with concurrent KRAS/STK11 and KRAS/KEAP1 mutations exhibit distinct immune characteristics.

JOURNAL OF THORACIC ONCOLOGY (2022)

Add to Collection
Article Oncology

Activity of adagrasib (MRTX849) in patients with KRASG12C-mutated NSCLC and active, untreated CNS metastases in the KRYSTAL-1 trial.

Joshua K. Sabari et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection
Article Chemistry, Medicinal

Design and Discovery of MRTX0902, a Potent, Selective, Brain- Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein Interaction

John M. Ketcham et al.

Summary: SOS1 is an important regulator of KRAS, and disrupting the SOS1:KRASG12C protein-protein interaction can increase the proportion of GDP-loaded KRASG12C. In this study, researchers designed and discovered MRTX0902, a potent and selective SOS1 binder that can disrupt the SOS1:KRASG12C interaction. Combining oral administration of MRTX0902 with MRTX849 has shown significant antitumor activity, including tumor regressions in a subset of animals in the MIA PaCa-2 tumor mouse xenograft model.

JOURNAL OF MEDICINAL CHEMISTRY (2022)

Add to Collection
Review Oncology

Non-genetic adaptive resistance to KRASG12C inhibition: EMT is not the only culprit

Wenjuan Ning et al.

Summary: Adaptations to therapeutic pressures in cancer cells, including non-genetic alterations and transcription factor reprogramming, enable the progression and resistance to therapy. KRAS(G12C) inhibitors have shown promise in cancer treatment, but face multiple resistance mechanisms. In addition to EMT, cancer cells can promote malignant phenotypes through rewiring signaling networks and manipulating the tumor microenvironment (TME).

FRONTIERS IN ONCOLOGY (2022)

Add to Collection
Article Medicine, General & Internal

Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation

Pasi A. Jaenne et al.

Summary: Adagrasib demonstrated clinical efficacy without new safety signals in previously treated KRAS(G12C)-mutated NSCLC patients.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection
Article Multidisciplinary Sciences

Therapeutic KRASG12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers

Edurne Mugarza et al.

Summary: Recently developed KRAS(G12C) inhibitory drugs benefit lung cancer patients with KRAS(G12C) mutations, but drug resistance is common. These drugs indirectly affect antitumor immunity by reversing immunosuppression caused by oncogenic KRAS. However, the combination of KRAS(G12C) inhibitors with immune checkpoint blockade only provides synergistic benefit in highly immunogenic tumor models.

SCIENCE ADVANCES (2022)

Add to Collection
Review Oncology

The treatment of advanced non-small cell lung cancer harboring KRAS mutation: a new class of drugs for an old target-a narrative review

Alessia Spagnuolo et al.

Summary: This paper provides an overview of the scientific efforts in KRAS inhibition, highlighting the approval of Sotorasib as the first KRAS G12C inhibitor that offers durable clinical benefit for pre-treated NSCLC patients with KRAS G12C mutation. The research also explores strategies combining KRAS inhibitors with other targeted therapies, chemotherapy, and immunotherapy.

TRANSLATIONAL LUNG CANCER RESEARCH (2022)

Add to Collection
Meeting Abstract Oncology

Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study

M. L. Johnson et al.

ANNALS OF ONCOLOGY (2022)

Add to Collection
Article Oncology

OA03.04 Phase I A Study to Evaluate GDC-6036 Monotherapy in Patients with Non-small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation

A. Sacher et al.

Journal of Thoracic Oncology (2022)

Add to Collection
Article Oncology

OA03.06 CodeBreaK 100/101: First Report of Safety/Efficacy of Sotorasib in Combination with Pembrolizumab or Atezolizumab in Advanced KRAS p.G12C NSCLC

B.T. Li et al.

Journal of Thoracic Oncology (2022)

Add to Collection
Article Oncology

OA03.07 Safety and Efficacy of D-1553 in Patients with KRAS G12C Mutated Non-Small Cell Lung Cancer: A Phase 1 Trial

S. Lu et al.

Journal of Thoracic Oncology (2022)

Add to Collection
Article Oncology

EP02.04-007 Phase 2 Trial of Neoadjuvant KRASG12C Directed Therapy with Adagrasib (MRTX849) With or Without Nivolumab in Resectable NSCLC (Neo-KAN)

S.C. Scott et al.

Journal of Thoracic Oncology (2022)

Add to Collection
Article Oncology

Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant Cancers

Husain Yar Khan et al.

Summary: The XPO1 inhibitor can enhance the anticancer activity of KRAS G12C inhibitors in preclinical cancer models. The combination treatment synergistically inhibits the proliferation of KRAS G12C mutant cancer cells and reduces tumor burden, leading to improved survival in vivo.

CANCER RESEARCH COMMUNICATIONS (2022)

Add to Collection
Article Oncology

Landscape of KRASG12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers

Mohamed E. Salem et al.

Summary: This study provides a comprehensive analysis of KRAS(G12C) mutations in various cancers, revealing its prevalence in females, older patients, and association with smoking status. KRAS(G12C) tumors exhibit distinct comutation profiles and are associated with high tumor mutational burden status.

JCO PRECISION ONCOLOGY (2022)

Add to Collection
Article Medicine, Research & Experimental

Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition

Yihsuan S. Tsai et al.

Summary: This study provides insights into the mechanisms of resistance to current KRAS G12C inhibitors in lung adenocarcinoma, including enrichment of clonal populations, KRAS-independent downstream signaling, and diverse remodeling of the tumor microenvironment.

JOURNAL OF CLINICAL INVESTIGATION (2022)

Add to Collection
Article Oncology

Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling

Chen Liu et al.

Summary: The study evaluated the efficacy and synergistic mechanisms of a novel SHP2 inhibitor, TNO155, in combination with various drugs in different cancer models. Results demonstrated that TNO155 effectively blocks tumor-promoting and immune-suppressive RTK signaling, providing a rationale for clinical evaluation of these combinations.

CLINICAL CANCER RESEARCH (2021)

Add to Collection
Article Oncology

NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes

Anju Singh et al.

Summary: Genomic alterations in KEAP1 and NFE2L2 lead to stabilization of the transcription factor NRF2 in a significant proportion of lung adenocarcinoma and squamous cell carcinoma patients. Experiments in genetically engineered mouse models reveal the oncogenic role of NRF2, particularly in promoting aggressive lung adenocarcinoma and affecting treatment responses. The NRF2 activation signature is associated with poor prognosis and limited response to anti-PD-L1 treatment in patients with nonsquamous or squamous tumors.

CLINICAL CANCER RESEARCH (2021)

Add to Collection
Review Oncology

Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives

Evgeny N. Imyanitov et al.

Summary: Molecular testing is essential in NSCLC management, including detecting mutations and translocations, as well as analyzing protein expression. Efforts are ongoing to integrate multiple molecular assays into a single diagnostic pipeline for NSCLC.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2021)

Add to Collection
Meeting Abstract Oncology

KRYSTAL-2: A phase I/II trial of adagrasib (MRTX849) in combination with TNO155 in patients with advanced solid tumors with KRAS G12C mutation.

Joshua K. Sabari et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection
Article Oncology

Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer

Luiz Henrique Araujo et al.

Summary: KRAS G12C mutation frequency is higher than other driver mutations in colorectal and non-small cell lung cancer, suggesting KRAS testing should be considered for all patients regardless of clinical or demographic characteristics.

BMC CANCER (2021)

Add to Collection
Article Oncology

Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer

Kathryn C. Arbour et al.

Summary: The study found that NSCLC patients with KRAS G12C mutations have similar clinical characteristics and treatment responses to those with KRAS non-G12C mutations, with no significant differences in response to immune checkpoint inhibitors.

CLINICAL CANCER RESEARCH (2021)

Add to Collection
Article Multidisciplinary Sciences

Diverse alterations associated with resistance to KRAS(G12C) inhibition

Yulei Zhao et al.

Summary: Resistance to KRAS(G12C) inhibitors demonstrates a heterogeneous pattern with multiple subclonal events emerging during treatment. Co-targeting of ERK signaling intermediates can enhance the antiproliferative effect of G12C inhibitor treatment in models with acquired RAS or BRAF mutations.

NATURE (2021)

Add to Collection
Article Oncology

Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project

Stephen P. Finn et al.

Summary: The specific Kr_G12C mutation is significantly associated with poorer prognosis in a large, clinically annotated stage I to III NSCLC cohort, particularly in adenocarcinomas. This mutation has a higher prevalence in adenocarcinomas and negatively impacts overall survival and relapse-free survival in patients with NSCLC.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection
Article Oncology

Loss of wild type KRAS in KRASMUT lung adenocarcinoma is associated with cancer mortality and confers sensitivity to FASN inhibitors

Yan Liu et al.

Summary: The study revealed that LAKR in KRAS(MUT) lung adenocarcinoma patients is significantly associated with cancer mortality, serving as a negative prognostic factor. Cells with LAKR show higher sensitivity to FASN inhibitors for treatment.

LUNG CANCER (2021)

Add to Collection
Article Multidisciplinary Sciences

CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer

Stanley Gutiontov et al.

Summary: The study found that the loss of CDKN2A function is associated with poorer clinical outcomes in advanced NSCLC patients treated with ICB, even in high PD-L1 and high TMB tumors. This novel finding should be further validated and may serve as a potential therapeutic target.

SCIENTIFIC REPORTS (2021)

Add to Collection
Review Oncology

Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR

Karan Seegobin et al.

Summary: ICI therapy in NSCLC shows promising outcomes in certain cases with actionable mutations, but its efficacy remains unclear in other cases. The correlation between PD-L1 expression or tumor mutation burden and treatment outcome is inconclusive.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection
Article Oncology

KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments

Takamasa Koga et al.

Summary: The study developed in vitro models of KRAS G12C cancer resistant to sotorasib and adagrasib, and found that most clones harbored secondary KRAS mutations which showed differential sensitivity to the inhibitors. Sequential use of sotorasib and adagrasib may be considered in some cases, while a combination of BI-3406 and trametinib could be an effective strategy to overcome resistance caused by secondary Y96D and Y96S mutations.

JOURNAL OF THORACIC ONCOLOGY (2021)

Add to Collection
Review Oncology

Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer

N. Coleman et al.

Summary: This article discusses MET amplification as a driver of acquired resistance in NSCLC, exploring the biology behind this mechanism and summarizing clinical data including proposed combination strategies for overcoming acquired MET amplification-dependent resistance.

ESMO OPEN (2021)

Add to Collection
Article Oncology

The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy

David M. Briere et al.

Summary: KRAS inhibition can reverse an immunosuppressive tumor microenvironment and sensitize tumors to checkpoint inhibitor therapy (CIT) through multiple mechanisms.

MOLECULAR CANCER THERAPEUTICS (2021)

Add to Collection
Article Oncology

Clinical Acquired Resistance to KRASG12C Inhibition through a novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation

Noritaka Tanaka et al.

Summary: This study described a patient with KRAS(G12C) non-small cell lung cancer who developed polyclonal acquired resistance to MRTX849 treatment. The research identified 10 heterogeneous resistance alterations that converged to reactivate the RAS-MAPK signaling pathway. Additionally, a novel KRAS(Y96D) mutation affecting key protein-drug interactions and driving resistance was discovered.

CANCER DISCOVERY (2021)

Add to Collection
Review Oncology

Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches

M. Reck et al.

Summary: KRAS is the most frequently mutated oncogene in human cancer, accounting for 85% of RAS mutations, yet there are no approved targeted therapies specifically for it. Promising direct KRAS(G12C) inhibitors such as sotorasib and adagrasib have shown clinical activity in previously treated patients, signaling a new era in the treatment of KRAS-mutated NSCLC.

ANNALS OF ONCOLOGY (2021)

Add to Collection
Review Biochemistry & Molecular Biology

Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment

D. Lucas Kerr et al.

Summary: SHP2, a nonreceptor protein tyrosine phosphatase, was considered 'undruggable' for decades, but has now become a potential target with the advent of allosteric inhibitors. These inhibitors show promise in preclinical cancer models and may also have immunomodulatory effects in certain tumor microenvironment cells. Clinical evaluation of the first generation of allosteric inhibitors will determine their safety, tolerability management, and antitumor efficacy for future applications.

CURRENT OPINION IN CHEMICAL BIOLOGY (2021)

Add to Collection
Review Biochemistry & Molecular Biology

Targeting Son of Sevenless 1: The pacemaker of KRAS

Dirk Kessler et al.

Summary: Son of Sevenless (SOS) is a guanine nucleotide exchange factor that plays a key role in activating the important cell signaling switch KRAS. Inhibition of SOS1 with potent inhibitors like BI-3406 has shown promising antiproliferative effects against various oncogenic KRAS mutants. The first SOS1 inhibitor has entered clinical trials for KRAS-mutated cancers, highlighting the potential therapeutic significance of targeting this pathway.

CURRENT OPINION IN CHEMICAL BIOLOGY (2021)

Add to Collection
Meeting Abstract Oncology

KRYSTAL-12: A randomized phase 3 study of adagrasib (MRTX849) versus docetaxel in patients (pts) with previously treated non-small-cell lung cancer (NSCLC) with KRASG12C mutation.

Tony S. K. Mok et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection
Article Multidisciplinary Sciences

Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells

Maria Casanova-Acebes et al.

Summary: Macrophages play a crucial role in shaping the tumor microenvironment and tumor immunity, with tissue-resident macrophages identified as key contributors to early lung cancer progression. Targeting tissue-resident macrophages may offer new possibilities for prevention and treatment of early lung cancer lesions.

NATURE (2021)

Add to Collection
Article Medicine, General & Internal

Acquired Resistance to KRASG12C Inhibition in Cancer

M. M. Awad et al.

Summary: A study of 38 patients with KRAS(G12C)-mutant cancers treated with adagrasib revealed diverse mechanisms of acquired resistance in 45% of them, including various mutations and bypass mechanisms. New therapeutic strategies are needed to overcome this drug resistance.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection
Article Oncology

Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer

Marcelo Negrao et al.

Summary: High TMB and PD-L1 expression are predictive for benefit from ICB treatment in oncogene-driven NSCLCs. NSCLC harboring BRAF mutations demonstrated superior benefit from ICB that may be attributed to higher TMB and higher PD-L1 expression in these tumors.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection
Review Oncology

KRAS G12C Mutations in NSCLC: From Target to Resistance

Alfredo Addeo et al.

Summary: This article discusses the role of KRAS in non-small cell lung cancer, including research on the mechanisms of resistance to KRAS G12C inhibitors and ways to overcome them. Additionally, advances in the treatment of non-small cell lung cancer, particularly with two therapeutic breakthroughs related to immune checkpoint inhibitors and oncogenic driver mutations targeting, are introduced.

CANCERS (2021)

Add to Collection
Article Medicine, Research & Experimental

Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer

Aparna Padhye et al.

Summary: This work received support from multiple sources including the National Institutes of Health, the Cancer Prevention & Research Institute of Texas, the University of Texas, and generous philanthropic contributions. The Flow Cytometry Lab at MD Anderson Cancer Center is supported by a Cancer Center Support Grant.

JCI INSIGHT (2021)

Add to Collection
Article Oncology

The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Jill Hallin et al.

CANCER DISCOVERY (2020)

Add to Collection
Article Oncology

A12 The SHP2 Inhibitor RMC-4630 in Patients with KRAS-Mutant Non-Small Cell Lung Cancer: Preliminary Evaluation of a First-in-Man Phase 1 Clinical Trial

S.I. Ou et al.

Journal of Thoracic Oncology (2020)

Add to Collection
Review Oncology

Targeting the MAPK Pathway in KRAS-Driven Tumors

Matthias Drosten et al.

CANCER CELL (2020)

Add to Collection
Review Oncology

KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures

Alex Friedlaender et al.

CANCER TREATMENT REVIEWS (2020)

Add to Collection
Article Chemistry, Medicinal

Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer

Jay B. Fell et al.

JOURNAL OF MEDICINAL CHEMISTRY (2020)

Add to Collection
Review Biochemistry & Molecular Biology

TargetingKRASMutant Non-Small-Cell Lung Cancer: Past, Present and Future

Iris Z. Uras et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Add to Collection
Article Chemistry, Multidisciplinary

Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs

Michael J. Bond et al.

ACS CENTRAL SCIENCE (2020)

Add to Collection
Article Chemistry, Medicinal

Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer

Matthew J. LaMarche et al.

JOURNAL OF MEDICINAL CHEMISTRY (2020)

Add to Collection
Article Oncology

A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER

Jonathan W. Goldman et al.

FRONTIERS IN ONCOLOGY (2020)

Add to Collection
Meeting Abstract Oncology

BI-3406 and BI 1701963: Potent and selective SOS1::KRAS inhibitors induce regressions in combination with MEK inhibitors or irinotecan

Daniel Gerlach et al.

CANCER RESEARCH (2020)

Add to Collection
Review Biochemistry & Molecular Biology

Regulation of cancer cell metabolism: oncogenic MYC in the driver's seat

Yang Dong et al.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)

Add to Collection
Article Oncology

Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC)

Arnaud Jeanson et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

Add to Collection
Review Medicine, General & Internal

KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition

Helen Adderley et al.

EBIOMEDICINE (2019)

Add to Collection
Article Oncology

K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways

Matthias Scheffler et al.

JOURNAL OF THORACIC ONCOLOGY (2019)

Add to Collection
Article Oncology

The Activity of Immune Checkpoint Inhibition in KRAS Mutated Non-small Cell Lung Cancer: A Single Centre Experience

Javier Torralvo et al.

CANCER GENOMICS & PROTEOMICS (2019)

Add to Collection
Review Oncology

Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy

Ferdinandos Skoulidis et al.

NATURE REVIEWS CANCER (2019)

Add to Collection
Review Oncology

Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy

Lais Osmani et al.

SEMINARS IN CANCER BIOLOGY (2018)

Add to Collection
Article Biochemistry & Molecular Biology

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

Matthew R. Janes et al.

CELL (2018)

Add to Collection
Article Biochemistry & Molecular Biology

Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C

Vincent L. Cannataro et al.

ONCOGENE (2018)

Add to Collection
Article Oncology

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma

Ferdinandos Skoulidis et al.

CANCER DISCOVERY (2018)

Add to Collection
Article Chemistry, Medicinal

Discovery and Structure-Based Optimization of Benzimidazole-Derived Activators of SOS1-Mediated Nucleotide Exchange on RAS

Timothy R. Hodges et al.

JOURNAL OF MEDICINAL CHEMISTRY (2018)

Add to Collection
Article Oncology

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Zhong-Yi Dong et al.

CLINICAL CANCER RESEARCH (2017)

Add to Collection
Article Oncology

Oncogenomics of c-Myc transgenic mice reveal novel regulators of extracellular signaling, angiogenesis and invasion with clinical significance for human lung adenocarcinoma

Yari Ciribilli et al.

ONCOTARGET (2017)

Add to Collection
Review Oncology

Prognostic value of EGFR and KRAS in circulating tumor DNA in patients with advanced non-small cell lung cancer: a systematic review and meta-analysis

Gaowei Fan et al.

ONCOTARGET (2017)

Add to Collection
Article Oncology

Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer

Megan L. Hames et al.

LUNG CANCER (2016)

Add to Collection
Review Biotechnology & Applied Microbiology

Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design

Jonathan M. L. Ostrem et al.

NATURE REVIEWS DRUG DISCOVERY (2016)

Add to Collection
Article Multidisciplinary Sciences

Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism

Piro Lito et al.

SCIENCE (2016)

Add to Collection
Review Cell Biology

Inflammation as a driver and vulnerability of KRAS mediated oncogenesis

Shunsuke Kitajima et al.

SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2016)

Add to Collection
Article Oncology

Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State

Matthew P. Patricelli et al.

CANCER DISCOVERY (2016)

Add to Collection
Article Oncology

Impact of KRAS mutation on response and outcome of patients with stageIII non-squamous non-small cell lung cancer

Shigehiro Yagishita et al.

CANCER SCIENCE (2015)

Add to Collection
Article Oncology

Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities

Ferdinandos Skoulidis et al.

CANCER DISCOVERY (2015)

Add to Collection
Editorial Material Oncology

Targeting cytokine networks in KRAS-driven tumorigenesis

Hadrien G. Golay et al.

EXPERT REVIEW OF ANTICANCER THERAPY (2014)

Add to Collection
Article Multidisciplinary Sciences

Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange

Michael C. Burns et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)

Add to Collection
Article Oncology

KRAS Mutation in Patients with Lung Cancer: A Predictor for Poor Prognosis but Not for EGFR-TKIs or Chemotherapy

Ji-lin Guan et al.

ANNALS OF SURGICAL ONCOLOGY (2013)

Add to Collection
Article Multidisciplinary Sciences

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

Jonathan M. Ostrem et al.

NATURE (2013)

Add to Collection
Article Chemistry, Multidisciplinary

Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-Mediated Activation

Qi Sun et al.

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)

Add to Collection
Article Oncology

Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers

Snjezana Dogan et al.

CLINICAL CANCER RESEARCH (2012)

Add to Collection
Article Multidisciplinary Sciences

Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity

Till Maurer et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)

Add to Collection
Letter Oncology

Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer

M. C. Garassino et al.

ANNALS OF ONCOLOGY (2011)

Add to Collection
Article Oncology

Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer

J Rinehart et al.

JOURNAL OF CLINICAL ONCOLOGY (2004)

Add to Collection
Article Cell Biology

Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism

JM Lambert et al.

NATURE CELL BIOLOGY (2002)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.